Synairgen Share Discussion Threads

[d1nga] 03/4/2020 14:24

one of the 7 dwarfs ?

[royalalbert] 03/4/2020 14:21

Nobby out of interest, your job is or was?

[nobbygnome] 03/4/2020 14:18

It is a completely different protein although in the same family. It's mainly used to treat hepatitis but its mechanism of action is not the same as beta interferon. It is more an adaptive immune response cytokine rather than the innate response, which means it takes a while to work. For an acute viral infection such as pneumonia beta interferon should be better.

But both are anti virals....

[likya123] 03/4/2020 14:11

Nobby, Synairgen are using Interferon - Beta - 1a.


Do you know the difference in this drug to Interferon Alfa-2b or are you currently busy buying as many shares that you can?!

The article above I believe is fairly significant as the say inhaled Interferon Alfa-2b works against covid-19 but will be of even more interest if Interferon Beta -1a is a superior drug.

[jev1] 03/4/2020 14:08

Suggests it's already proven to work. :o)


With a Google search:

_____







Interferon Alfa-2b is currently used in vulnerable and health care personnel as a preventive measure, as well as in patients with COVID-19 in the form of a nebulisation, as it is a quick route to reach the lungs and act in the early stages of the infection, according to president of the pharmaceutical company BioCubaFarma group, Eduardo Martinez.

[likya123] 03/4/2020 14:01

Yeah Nobby, inhaled.

So is this inferior to what Synairgen is using and if so is this post not then quite a significant find?

[nobbygnome] 03/4/2020 13:55

Whoops didn't see that...... so it has a better chance of working.

[alphatim] 03/4/2020 13:53

Inhaled not injected

[nobbygnome] 03/4/2020 13:43

Alfa 2b interferon is a different protein to beta interferon and is not such a good anti viral. Plus it will be an injected form so the chances of it working are low.

[likya123] 03/4/2020 13:34

Another great post from lse board..

Apparently widely used in China and now other territories in the OECS in inhaled form to treat Covid-19. Has proved effective in the treatment of the disease. Now, I'm no scientist so cannot comment on the similarity of this drug/substance to Synairgen's, but there is seemingly plenty of available anecdotal evidence of interferon's effectiveness treating the virus. Article to be found on the Trinidad Express website should anyone be so inclined. 

An except below from 16th March:
According to a CMC report, Gonzales said the OECS pharmaceutical services has also placed an additional order of the same drug for St Vincent and the Grenadines and for the other member states of the sub-region.
“So we are ordering ourselves directly and also the OECS is doing it for us and the other eight members of the OECS,” Gonsalves said, adding that the OECS purchases are being made from resources provided by St Kitts-based Eastern Caribbean Central Bank (ECCB), which serves as a central bank for the OECS members.
“I have been in communication with the Governor of the Central Bank, Mr Timothy Antoine, on this matter and so, too, has the Minister of Finance Camillo (Gonsalves),” Gonzales said.

“I have been advised that the drug Interferon strengthens the immune system of a person to fight viruses. It is essentially, I have been advised, an antiviral pharmaceutical product.” he added.
Venezuela buys in
Next door, Venezuelan President Nicolas Maduro last Thursday disclosed that Cuba has already delivered 10,000 dosages of the drug to Venezuela.
At the Miraflores Presidential Palace in Caracas, Maduro said: “From Cuba we have received 10,000 doses of Interferon Alfa-2b, which has been one of the most successful treatments to recover the health of patients and save their lives,”

[makendon] 03/4/2020 12:19

PDT, (& all)

I use Readly to get access to almost all mags - incl moneyweek, shares, moneywise, money observer available on day of hard copy release. Plus hundreds of others - £7.99/ mth. 2 months free at the moment;



Or use the following link and we both get free months for recommending ;)



I’ve used it for over a year without a problem.

Enjoy!

[bobaxe1] 03/4/2020 11:49

Yes their ratings states 120 and with positive results a further up side. 360 was mentioned

[wetdream] 03/4/2020 11:48

It’d be a bit sad if the co’s NOMAD couldn’t come up with a +ve note!
;-)

[pdt] 03/4/2020 11:42

Likya - good spot, I like Moneyweek mag. Weekly circulation was 35,000 not sure how many now, I used to pick mine up from WH Smith (now closed).

[likya123] 03/4/2020 11:27

SNG is one of the "Three to buy"

[toffeeman] 03/4/2020 11:14

I'll take 120 at this point in time

[nobbygnome] 03/4/2020 11:05

To be fair to him the note does say 360p on the back of a positive result so strictly speaking an accurate statement.

[makendon] 03/4/2020 11:02

Bob / likya

Last update from finncap from 31\03 - clearly states £1.20



Sector: Life Sciences

Synairgen (SNG) : Corp

First COVID-19 patient dosed

Key data

Share price (p) 62.0
Target price (p) 120.0
Market cap (£m) 92.6
Enterprise value (£m) 90.2

Misleading information does nothing for shareholder confidence

[likya123] 03/4/2020 10:54

FINNCAP NOTE - 31 MAR 2020
£3.60 TARGET

Synairgen*

First COVID-19 patient dosed

Synairgen confirmed that it has commenced dosing patients in its Phase II trial of SNG001 (inhaled formulation of interferon-beta-1a) in COVID-19 patients, the first patient having been enrolled at University Hospital Southampton. A further six sites have been initiated, which are expected to start dosing in the coming days.

These sites, together with potentially three more, should enable the company to complete enrolment during April. Clearly this is a positive development and testament to the efforts of Synairgen, regulators and clinicians to help COVID-19
patients, with results expected during Q2 2020 that will determine the next action points. We reiterate our 120p target price with the prospect that this would rise by up to 240p on a positive outcome.

• First patient dosed.
The first patient has been dosed at the initial trial site at University Hospital Southampton NHS Foundation Trust. Synairgen has initiated a further 6 trial sites which are expected to start dosing in the coming days, having
previously indicated that it expects c.10 sites to participate in the trial.

• Clinical trial summary.
It is a double-blind placebo-controlled Phase II trial in hospitalised COVID-19 patients (not yet on ventilator) that will enrol 100 patients. As indicated in our report of 26 March, we think that results could be generated during Q2 2020, given an estimated two weeks to complete enrolment, two weeks to complete dosing, with a further 2-4 weeks of follow-up followed by analysis of data.

•Valuation.
We reiterate our rNPV-based target price of 120p, of which c.80p relates to the use of SNG001 in COVID-19 disease. The successful completion of the Phase II study (SG016) would imply a rNPV of as much as c.£475m or a c.360p target price – suggesting a c.£360m (240p) uplift on the current estimated NPV.

[makendon] 03/4/2020 10:47

Bob, share the link where you found that forecast sp

[bobaxe1] 03/4/2020 10:39

Finncap forecast 360p!!

[hazl] 03/4/2020 10:30

the above is general but interesting time scale for closing shops and so on.

[hazl] 03/4/2020 10:29

thanks to james